Therapy Area topics
Cardiovascular
Leviticus Cardio charges towards the market
A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
Central Nervous System
Upcoming events – pivotal readouts for Intra-Cellular and Myovant
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Diabetes
ISN 2019 – Kidney benefit could help Invokana compete again
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
Poxel tastes sweet success at last
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
Upcoming events – Novo takes aim at type 1 diabetes and Aslan wants to roar
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
Digital Health
Fewer than 200 medtech VC rounds closed in 2018
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Oncology
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Respiratory
Savara hopes to take a leaf out of Insmed’s book
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
The bubble bursts for Proteostasis
Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to.
Circassia finds a second way to put investors’ money under threat
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Various
Big-bucks first quarter masks drop in deal volume
Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.
Another knock back for urea cycle disorders
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.